PT  - JOURNAL ARTICLE
AU  - Bramante, Carolyn T
AU  - Beckman, Kenneth B
AU  - Mehta, Tanvi
AU  - Karger, Amy B
AU  - Odde, David J
AU  - Tignanelli, Christopher J
AU  - Buse, John B
AU  - Johnson, Darrell M
AU  - Watson, Ray H. B.
AU  - Daniel, Jerry J
AU  - Liebovitz, David M
AU  - Nicklas, Jacinda M
AU  - Cohen, Kenneth
AU  - Puskarich, Michael A
AU  - Belani, Hrishikesh K
AU  - Siegel, Lianne K
AU  - Klatt, Nichole R
AU  - Anderson, Blake
AU  - Hartman, Katrina M
AU  - Rao, Via
AU  - Hagen, Aubrey A
AU  - Patel, Barkha
AU  - Fenno, Sarah L
AU  - Avula, Nandini
AU  - Reddy, Neha V
AU  - Erickson, Spencer M
AU  - Fricton, Regina D.
AU  - Lee, Samuel
AU  - Griffiths, Gwendolyn
AU  - Pullen, Matthew F
AU  - Thompson, Jennifer L.
AU  - Sherwood, Nancy
AU  - Murray, Thomas A.
AU  - Rose, Michael R.
AU  - Boulware, David R
AU  - Huling, Jared D.
AU  - ,
TI  - Metformin reduces SARS-CoV-2 in a Phase 3 Randomized Placebo Controlled Clinical Trial
AID  - 10.1101/2023.06.06.23290989
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.06.06.23290989
4099  - http://medrxiv.org/content/early/2023/06/07/2023.06.06.23290989.short
4100  - http://medrxiv.org/content/early/2023/06/07/2023.06.06.23290989.full
AB  - Current antiviral treatment options for SARS-CoV-2 infections are not available globally, cannot be used with many medications, and are limited to virus-specific targets.1-3 Biophysical modeling of SARS-CoV-2 replication predicted that protein translation is an especially attractive target for antiviral therapy.4 Literature review identified metformin, widely known as a treatment for diabetes, as a potential suppressor of protein translation via targeting of the host mTor pathway.5 In vitro, metformin has antiviral activity against RNA viruses including SARS-CoV-2.6,7 In the COVID-OUT phase 3, randomized, placebo-controlled trial of outpatient treatment of COVID-19, metformin had a 42% reduction in ER visits/hospitalizations/death through 14 days; a 58% reduction in hospitalizations/death through 28 days, and a 42% reduction in Long COVID through 10 months.8,9 Here we show viral load analysis of specimens collected in the COVID-OUT trial that the mean SARS-CoV-2 viral load was reduced 3.6-fold with metformin relative to placebo (−0.56 log10 copies/mL; 95%CI, -1.05 to -0.06, p=0.027) while there was no virologic effect for ivermectin or fluvoxamine vs placebo. The metformin effect was consistent across subgroups and with emerging data.10,11 Our results demonstrate, consistent with model predictions, that a safe, widely available,12 well-tolerated, and inexpensive oral medication, metformin, can be repurposed to significantly reduce SARS-CoV-2 viral load.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov: NCT04510194Funding StatementThe fluvoxamine placebo tablets were donated by the Apotex pharmacy. The ivermectin placebo and active tablets were donated by the Edenbridge pharmacy. The trial was funded by the Parsemus Foundation, Rainwater Charitable Foundation, Fast Grants, and the United Health Foundation. The funders had no influence on the design or conduct of the trial and were not involved in data collection or analysis, writing of the manuscript, or decision to submit for publication. The authors assume responsibility for trial fidelity and the accuracy and completeness of the data and analyses. Dr. Bramante was supported by grants (KL2TR002492 and UL1TR002494) from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and by a grant (K23 DK124654) from the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH. Dr. Buse was supported by a grant (UL1TR002489) from NCATS. Dr. Nicklas was supported by a grant (K23HL133604) from the National Heart, Lung, and Blood Institute of the NIH. Dr. Odde was supported by the Institute for Engineering in Medicine, UMN Office of Academic and Clinical Affairs COVID-19 Rapid Response Grant, the Earl E. Bakken Professorship for Engineering in Medicine, and by grants (U54 CA210190 and P01 CA254849) from the National Cancer Institute of the NIH. Dr. Murray was supported in part by the Medtronic Faculty Fellowship. Dr. Liebovitz receives funding from NIH RECOVER (OT2HL161847). Dr. Siegel was supported by NIH grants (18X107CF6 and 18X107CF5) through a contract with Leidos Biomedical and by grants from National Heart, Lung, and Blood Institute of the NIH (T32HL129956), and the NIH (R01LM012982 and R21LM012744). Dr. Puskarich receives grants from Bill and Melinda Gates Foundation (INV-017069), Minnesota Partnership for Biotechnology and Medical Genomics (00086722), National Heart, Lung, and Blood Institute of the NIH (OT2HL156812).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of Advarra gave ethical approval for this work (MET29324).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData availability The data for this manuscript, as well as the code used to generate the results, will be made freely available for individuals with a defined research question within approximately 1 month of it being published. https://covidout.umn.edu